Status:
COMPLETED
The Molecular Mechanism of RAS Wild-type mCRC Resistance to Anti-EGFR-antibody
Lead Sponsor:
Sun Yat-sen University
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
Establishing the genetic map of primary and secondary resistance of Chinese wild RAS colorectal cancer received anti-EGFR treatment through tissues and peripheral blood NGS testing. Combination geneti...
Detailed Description
Cetuximab is a chimeric (mouse/human) monoclonal antibody, an epidermal growth factor receptor (EGFR) inhibitor. Many large clinical trials demonstrated that for RAS wild-type metastatic colorectal ca...
Eligibility Criteria
Inclusion
- Age≥18 years, ≤75 years, all gender;
- Histologically proven metastatic adenocarcinoma of colorectal cancer, no previous history of cancer;
- The clinical data of patient is intact;
- The data of patients after surgery is intact, and the prognosis follow-up data of patient is available.
Exclusion
- Previous history of cancer；
- Intact clinical data or diagnosis results of histopathology is unavailable;
- Time of progression disease after treatment and follow-up data are unavailable;
- Patient received blood transfusion within 3 months;
- Other situation that researchers think it will impact the results of trails or violate ethics.
Key Trial Info
Start Date :
March 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 4 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04466267
Start Date
March 1 2017
End Date
July 4 2020
Last Update
July 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Oncology,Sun Yat-sen University Cancer Center
Guanzhou, Guangdong, China, 510060